What is not working for the company?
What is working for the company?
|Name||Sep 22||Jun 22|
|Mutual Funds (Change:0.00)||0.04%||0.04%|
|Insurance Companies (Change:0.00)||0%||0%|
|Other DIIs (Change:0.00)||0%||0%|
|Non Institution (Change:0.00)||64.52%||64.52%|
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in VISTA PHARMACEUTICALS LTD.
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
Frequently Asked Questions
What is the Share price of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
Can I buy VISTA PHARMACEUTICALS LTD. (VISTAPH) shares?
How do I buy VISTA PHARMACEUTICALS LTD. (VISTAPH) from Angel One?
- Direct investment: You can buy VISTA PHARMACEUTICALS LTD. (VISTAPH) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to VISTA PHARMACEUTICALS LTD. (VISTAPH) shares.
In which sector do VISTA PHARMACEUTICALS LTD. (VISTAPH) belong?
Today's live share price for VISTA PHARMACEUTICALS LTD. is NSE: N/A, BSE: ₹ 7.92 with a current market capitalization of .
Vista Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in the formulation of pharmaceutical products. The company offers a range of products mainly in the therapeutic areas of gastrointestinal, pain management and anti-infective, catering to common ailments. This division is a primary contributor to the domestic sales of Torrent Pharmaceuticals Ltd. The company is based in Hyderabad, India. Vista Pharmaceuticals Limited was incorporated on January 25,1991 under the Companies Act of 1956 with the Registrar of Companies Andhra Pradesh & has obtained Certificate of Commencement of Business on February 7, 1991. Vista Pharmaceuticals was incorporated by Dr. Dhananjaya Alli & his associates. The capital was subscribed by Vista Pharmaceuticals Inc., an Overseas Corporate Body promoted by them as a per the laws of State of New Jersy, United States of America. During the fiscal year ended March 31, 2010 (fiscal 2010), the Company obtained the United States Food and Drug Administration (FDA) approval for the manufacture of Bactrim generic product. During fiscal 2010, the Company produced 20.488 million numbers of tablets. The Company was in process of setting up a 100% EOU for manufcacture of drug formulations with an installed capacity of 400 million tablets & 200 million capsules per annum.Read more